Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report

Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute poste...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutzenbach, Johannes Sebastian, Pikija, Slaven, Otto, Ferdinand, Halwachs, Ursula, Weymayr, Friedrich, Sellner, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099535/
https://www.ncbi.nlm.nih.gov/pubmed/27844035
http://dx.doi.org/10.1002/acn3.346
_version_ 1782465983542198272
author Mutzenbach, Johannes Sebastian
Pikija, Slaven
Otto, Ferdinand
Halwachs, Ursula
Weymayr, Friedrich
Sellner, Johann
author_facet Mutzenbach, Johannes Sebastian
Pikija, Slaven
Otto, Ferdinand
Halwachs, Ursula
Weymayr, Friedrich
Sellner, Johann
author_sort Mutzenbach, Johannes Sebastian
collection PubMed
description Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute posterior circulation ischemic stroke after dabigatran reversal with idarucizumab. Both treatments were well tolerated and no hemorrhagic or procoagulatory complications were observed. We propose that the option of dabigatran reversal needs to be considered for contemporary treatment concepts of acute ischemic stroke.
format Online
Article
Text
id pubmed-5099535
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50995352016-11-14 Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report Mutzenbach, Johannes Sebastian Pikija, Slaven Otto, Ferdinand Halwachs, Ursula Weymayr, Friedrich Sellner, Johann Ann Clin Transl Neurol Case Study Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute posterior circulation ischemic stroke after dabigatran reversal with idarucizumab. Both treatments were well tolerated and no hemorrhagic or procoagulatory complications were observed. We propose that the option of dabigatran reversal needs to be considered for contemporary treatment concepts of acute ischemic stroke. John Wiley and Sons Inc. 2016-09-17 /pmc/articles/PMC5099535/ /pubmed/27844035 http://dx.doi.org/10.1002/acn3.346 Text en © 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Study
Mutzenbach, Johannes Sebastian
Pikija, Slaven
Otto, Ferdinand
Halwachs, Ursula
Weymayr, Friedrich
Sellner, Johann
Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title_full Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title_fullStr Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title_full_unstemmed Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title_short Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
title_sort intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
topic Case Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099535/
https://www.ncbi.nlm.nih.gov/pubmed/27844035
http://dx.doi.org/10.1002/acn3.346
work_keys_str_mv AT mutzenbachjohannessebastian intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport
AT pikijaslaven intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport
AT ottoferdinand intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport
AT halwachsursula intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport
AT weymayrfriedrich intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport
AT sellnerjohann intravenousthrombolysisinacuteischemicstrokeafterdabigatranreversalwithidarucizumabacasereport

Ejemplares similares